Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

GASTROCLEAR™ GRANTED CHINA NMPA IVD REGISTRATION CERTIFICATE FOR GASTRIC CANCER SCREENING

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that its core product GASTROClear™, an in vitro diagnostic ("**IVD**") test, has received approval as a Class III Medical Device by the National Medical Products Administration of China (the "**NMPA**"), for non-invasive screening of gastric cancer in China. This is the first blood test approved by NMPA for gastric cancer screening.

GASTROClear™ is the world's first microRNA ("**miRNA**") blood test approved for the early detection of gastric cancer, evaluating gastric cancer risk by detecting 12 gastric cancer-associated miRNA biomarkers. Previously, the product obtained approval in Singapore in 2019 and received the "Breakthrough Device" designation from the U.S. Food and Drug Administration ("**FDA**") in 2023. The approval by NMPA in China marks yet another significant milestone for the Company in its transition from research and development to commercialization, and also reflects its achievements in technological advancement, large-scale clinical trials, backed by its long-term commitment and investment in innovation and market access.

Based on the approved intended use, GASTROClear™ is approved for screening of adults aged 45–74 who are at high risk for gastric cancer, as defined by the "Chinese Guidelines for Gastric Cancer Screening and Early Diagnosis and Treatment (2024 Edition)," potentially covering a population exceeding 500 million. The product will be deployed as an IVD test in both public and private medical institutions across China, significantly expanding the Company's business reach within the Chinese gastric cancer screening market.

Looking ahead, the Company will continue to expand its investment in scaling commercialization in China, including increasing the size of its sales team and enhancing local production capacity. Simultaneously, the Company will further strengthen its business development and collaboration (BD) efforts in Mainland China to drive broader adoption of the product.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GASTROClear™ will ultimately be successfully commercialized at scale by the Company.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, October 9, 2025

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan, Dr. ZOU Ruiyang and Mr. HO Hou Chiat, Isaac as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.